On April 5, 2022, Kurt Gustafson notified ChromaDex Corporation of his intention not to stand for re-election as director of Board of Directors of the Company and as a member of the Audit Committee and Compensation Committee of the Board. Mr. Gustafson will remain on the Board and the Board committees until the Annual Meeting of Stockholders which is expected to be held in June 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.98 USD | -6.88% |
|
-6.88% | +108.39% |
Jun. 13 | Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® | CI |
Jun. 07 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+108.39% | 226M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- CDXC Stock
- News ChromaDex Corporation
- Kurt Gustafson Announces Not to Stand for Re-Election as director of Board of Directors of the Company and as a member of the Audit Committee and Compensation Committee of the Board of ChromaDex Corporation